Evaxion Biotech (EVAX) has released an update.
Evaxion Biotech has entered into a patent co-ownership agreement with the Statens Serum Institut, effective June 27, 2024, granting Evaxion the rights to administer commercial interests of jointly owned patents. Under the agreement, Evaxion holds exclusive rights to commercial exploitation, while SSI acknowledges that all commercial rights rest with Evaxion, except as outlined in separate written agreements.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
